Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NUWE
stocks logo

NUWE

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
2.50M
+5.62%
-1.560
-91.56%
2.31M
-0.52%
-0.700
-97.58%
--
--
-0.590
-99.03%
Estimates Revision
The market is revising No Change the revenue expectations for Nuwellis, Inc. (NUWE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -46.11%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-46.11%
In Past 3 Month
Wall Street analysts forecast NUWE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUWE is 3.90 USD with a low forecast of 3.90 USD and a high forecast of 3.90 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast NUWE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUWE is 3.90 USD with a low forecast of 3.90 USD and a high forecast of 3.90 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
Current: 2.630
sliders
Low
3.90
Averages
3.90
High
3.90
Current: 2.630
sliders
Low
3.90
Averages
3.90
High
3.90
Roth Capital
Jonathan Aschoff
Buy
downgrade
$13 -> $11
2025-05-13
Reason
Roth Capital
Jonathan Aschoff
Price Target
$13 -> $11
2025-05-13
downgrade
Buy
Reason
Roth Capital analyst Jonathan Aschoff lowered the firm's price target on Nuwellis to $11 from $13 and keeps a Buy rating on the shares. While the company's Q1 revenue was down 18% quarter over quarter, pediatric utilization grew 38% year over year, the analyst tells investors in a research note. The firm believes that the four-fold increase in Aquadex Centers for Medicare & Medicaid Services reimbursement should support future revenue growth.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Nuwellis Inc (NUWE.O) is -0.72, compared to its 5-year average forward P/E of -0.74. For a more detailed relative valuation and DCF analysis to assess Nuwellis Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.74
Current PE
-0.72
Overvalued PE
-0.14
Undervalued PE
-1.33

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.20
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.56
Undervalued EV/EBITDA
-0.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.91
Current PS
0.00
Overvalued PS
1.80
Undervalued PS
0.01
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

NUWE News & Events

Events Timeline

(ET)
2025-12-04
08:20:00
Nuwellis Launches Aquadex Ultrafiltration Program at Northeastern U.S. Children's Hospital
select
2025-11-12 (ET)
2025-11-12
08:17:36
Nuwellis Announces Q3 Earnings Per Share of 56 Cents
select
2025-11-10 (ET)
2025-11-10
09:05:46
Nuwellis Granted Notice of Allowance for U.S. Patent on Vivian System
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
12-04Globenewswire
Nuwellis Launches Aquadex Ultrafiltration Program at Leading Children's Hospital
  • Market Expansion: Nuwellis has initiated the Aquadex Ultrafiltration Program at a leading children's hospital in the Northeastern U.S., marking a significant step in its ongoing growth within the pediatric market, which is expected to enhance the company's market share in fluid management.
  • Clinical Value Enhancement: The adoption of Aquadex is accelerating in high-acuity pediatric settings, as children's hospitals integrate the therapy into care pathways for complex cardiac and renal cases, demonstrating the trust and clinical value physicians see in this therapy.
  • Technological Advantage: The Aquadex system features real-time hematocrit monitoring, allowing clinical teams to directly assess patient tolerance during fluid removal, thereby enhancing support for fragile pediatric disease states.
  • Strategic Commitment: Nuwellis CEO John Erb noted that the demand from pediatric clinicians for Aquadex is driving the company's growth, highlighting the strategic importance of the pediatric market and its potential for future development.
[object Object]
Preview
5.0
12-04Yahoo Finance
Nuwellis Expands Clinician-Led Pediatric Care Collaboration with Top Northeast U.S. Hospital

  • Aquadex Ultrafiltration Program Launch: A leading children's hospital in the Northeastern U.S. has initiated an Aquadex Ultrafiltration Program, reflecting the growing interest from pediatric nephrology and cardiology teams in managing fluid-sensitive patients.

  • Adoption in Pediatric Care: Aquadex is increasingly being integrated into care pathways for complex cardiac and critical care cases in children's hospitals nationwide, highlighting its clinical value and the strategic importance of the pediatric market for Nuwellis.

  • Clinician-Driven Growth: The adoption of Aquadex is primarily driven by pediatric clinicians seeking reliable solutions for fluid volume management, which enhances patient safety and control compared to traditional methods.

  • Commitment to Pediatric Specialists: Nuwellis is dedicated to supporting pediatric specialists as Aquadex becomes more widely utilized in complex care environments, emphasizing its role in modern pediatric fluid-management strategies.

[object Object]
Preview
9.5
11-12NASDAQ.COM
Nuwellis, Inc. Reports Decrease in Profit for Q3

  • Earnings Decline: Nuwellis, Inc. reported a significant drop in earnings for the third quarter, with earnings of $0.469 million or $0.56 per share, down from $2.35 million or $73.23 per share last year.

  • Revenue Decrease: The company's revenue fell by 6.4% to $2.21 million compared to $2.36 million in the same period last year.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Nuwellis Inc (NUWE) stock price today?

The current price of NUWE is 2.63 USD — it has increased 12.39 % in the last trading day.

arrow icon

What is Nuwellis Inc (NUWE)'s business?

Nuwellis, Inc. is a commercial-stage medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.

arrow icon

What is the price predicton of NUWE Stock?

Wall Street analysts forecast NUWE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUWE is 3.90 USD with a low forecast of 3.90 USD and a high forecast of 3.90 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Nuwellis Inc (NUWE)'s revenue for the last quarter?

Nuwellis Inc revenue for the last quarter amounts to 2.22M USD, decreased -6.34 % YoY.

arrow icon

What is Nuwellis Inc (NUWE)'s earnings per share (EPS) for the last quarter?

Nuwellis Inc. EPS for the last quarter amounts to 0.56 USD, decreased -99.24 % YoY.

arrow icon

What changes have occurred in the market's expectations for Nuwellis Inc (NUWE)'s fundamentals?

The market is revising No Change the revenue expectations for Nuwellis, Inc. (NUWE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -46.11%.
arrow icon

How many employees does Nuwellis Inc (NUWE). have?

Nuwellis Inc (NUWE) has 38 emplpoyees as of December 05 2025.

arrow icon

What is Nuwellis Inc (NUWE) market cap?

Today NUWE has the market capitalization of 4.36M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free